You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《瑞通窩輪》【瑞通認股證牛熊證】石藥八日累挫18%考驗百天線 銀娛上試10及50天線 石藥購27547 熊63134/ 銀河購24070 沽12901/ 吉利牛64261 熊62744
阿思達克 12-10 10:25

市場觀望今周歐美議息、英國大選、中美貿易談判等多項重要經濟及政治事件發展,道指隔晚收報27909點,跌105點(或0.4%)。

恆指昨好淡爭持,收報26494點,跌3點。今早曾跌逾100點,其後於26400點附近整固。恆指好倉(牛證及認購權證)昨淨流入48萬港元(下同),恆指淡倉(熊證及認沽權證)同日淨流入逾2800萬元,反映較多投資者看淡港股後市。昨日恆指牛證街貨重貨區為收回價25900至25999點,而熊證街貨重貨區為收回價27000至27099點。

市傳內地第三輪藥品集採規則流出,有券商估計今輪集採中標價仍會明顯降價,醫藥股昨繼續捱沽。石藥(01093)昨挫逾半成,險守17元收市,是表現最差藍籌,盤中最多跌6.2%至16.82元,回至十月時水平。石藥於11月29日裂口下跌,八個交易日最多累跌達18%。股份今早跌勢持續,曾下試16.7元水平,留意下方100天線(約16.5元)的支持力度。昨分別有260萬元和43萬元淨流入其好倉和淡倉。

有券商指中央對內房行業釋出正面訊號,料會放鬆房策,帶動內房股昨受資金追捧。碧桂園(02007)昨曾升抵一個月高位11.56元,其後升勢回順,收升1.6%於11.32元,企於各平均線之上。今早大致靠穩,於11.4元之下徘徊。昨分別有近140萬元和1萬元淨流入其好倉和淡倉。

銀娛(00027)日前錄大手成交,但昨日股價波幅不大,大致於52元附近窄幅上落。銀娛今早變動不大,在52元附近徘徊,逐步企穩10及50天線(同於52元)。昨有56萬元淨流入其好倉,淡倉同日亦有近210萬元淨流入。

友邦(01299)是昨日最多北水經港股通淨流出的股份,單日淨流出1.68億元。股份昨續於20天(78.4元)和50天線(77.2元)區間內上落,收報77.6元,今早於77元上落。昨分別有17萬元和11萬元淨流入其好倉和淡倉。

瑞通相關認股證之選擇:

石藥貼價、中短期購27547,行使價:17.38元,2020年4月到期,實際槓桿:4.9倍

石藥輕微價外、中年期沽28344,行使價:14.68元,2020年7月到期,實際槓桿:3.4倍

碧桂輕微價外、短期購18754,行使價:12.12元,2020年2月到期,實際槓桿:8倍

銀河輕微價外、中短期購24070,行使價:58.8元,2020年4月到期,實際槓桿:8.3倍

銀河貼價、中短期沽12901,行使價:51.8元,2020年6月到期,實際槓桿:4.2倍

友邦貼價、中短期購13595,行使價:79.95元,2020年3月到期,實際槓桿:9.8倍

友邦貼價、中短期沽13262,行使價:75元,2020年6月到期,實際槓桿:6.3倍

阿里輕微價外、中短期購13507,行使價:208元,2020年5月到期,實際槓桿:5.9倍

瑞通相關牛熊證之選擇:

恆指N類牛證58812,收回價及行使價:25820點,槓桿比率:37.3倍

恆指熊證63720,收回價:26990點,槓桿比率:36.7倍

石藥牛證63136,收回價:16.2元,槓桿比率:10.3倍

石藥熊證63134,收回價:19.3元,槓桿比率:5.3倍

銀河牛證61488,收回價:48.6元,槓桿比率:10倍

銀河熊證60495,收回價:55.5元,槓桿比率:10.6倍

友邦牛證62682,收回價:73.6元,槓桿比率:14.6倍

友邦熊證62466,收回價:80.8元,槓桿比率:18.9倍

美團牛證62230,收回價:97.51元,槓桿比率:12.4倍

美團熊證62736,收回價:105.7元,槓桿比率:11.3倍

吉利牛證64261,收回價:13.9元,槓桿比率:8.4倍

吉利熊證62744,收回價:15.9元,槓桿比率:8.4倍重要風險通知

本結構性產品並無抵押品。

結構性產品之價格一般可急升亦可急跌,有可能損失結構性產品之全部或重大部分購買價,閣下對此應有所準備。

閣下投資前應了解產品風險,如有需要應諮詢專業建議。~重要聲明:

以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account